
Fierce Pharma Asia—WuXi Bio's plunge; Daiichi-Novartis $182M settlement; Merck KGaA's Abbisko deal
WuXi Biologics' gloomy business update triggered a stock market avalanche. Daiichi Sankyo and Novartis reached a $182 million settlement on their BRAF drug patent dispute. Merck KGaA linked up with China's Abbisko Therapeutics on a phase 3 joint …